Dermata Therapeutics, Inc. financial data

Symbol
DRMA, DRMAW on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 37% % -1.8%
Return On Equity -192% % 22%
Return On Assets -140% % 22%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,026,457 shares -50%
Common Stock, Shares, Outstanding 844,457 shares -50%
Entity Public Float $1,600,000 USD -67%
Common Stock, Value, Issued $84 USD -50%
Weighted Average Number of Shares Outstanding, Basic 1,026,457 shares 560%
Weighted Average Number of Shares Outstanding, Diluted 1,026,457 shares 560%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $4,595,852 USD -36%
General and Administrative Expense $4,045,650 USD -9.5%
Operating Income (Loss) $9,073,492 USD 21%
Net Income (Loss) Attributable to Parent $8,847,606 USD 21%
Earnings Per Share, Basic 57 USD/shares 92%
Earnings Per Share, Diluted 57 USD/shares 92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,664,127 USD
Assets $5,071,410 USD -24%
Accounts Payable, Current $453,427 USD -47%
Employee-related Liabilities, Current $594,144 USD
Liabilities $1,111,308 USD -43%
Retained Earnings (Accumulated Deficit) $71,372,008 USD -14%
Stockholders' Equity Attributable to Parent $3,960,102 USD -16%
Liabilities and Equity $5,071,410 USD -24%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,934,066 USD 28%
Net Cash Provided by (Used in) Financing Activities $8,491,764 USD
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 844,457 shares -50%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,557,698 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,664,127 USD -24%
Deferred Tax Assets, Valuation Allowance $8,015,000 USD 47%
Deferred Tax Assets, Gross $8,015,000 USD 47%
Deferred Tax Assets, Operating Loss Carryforwards $4,270,000 USD 43%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $764,000 USD 18%
Additional Paid in Capital $75,332,026 USD 12%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares